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Abstract
Background: The stem cell marker Octamer-4 (OCT-4) is expressed in human endometrium. Menstrual cycle-
dependency of OCT-4 expression has not been investigated to date.
Methods: In a prospective, single center cohort study of 98 women undergoing hysteroscopy during the follicular (n = 
49) and the luteal (n = 40) phases of the menstrual cycle, we obtained endometrial samples. Specimens were 
investigated for OCT-4 expression on the mRNA and protein levels using reverse transcriptase polymerase chain 
reaction (RT-PCR) and immunohistochemistry. Expression of OCT-4 was correlated to menstrual cycle phase.
Results: Of 89 women sampled, 49 were in the follicular phase and 40 were in the luteal phase. OCT-4 mRNA was 
detected in all samples. Increased OCT-4 mRNA levels in the follicular and luteal phases was found in 35/49 (71%) and 
27/40 (68%) of women, respectively (p = 0.9). Increased expression of OCT-4 protein was identified in 56/89 (63%) 
samples. Increased expression of OCT-4 protein in the follicular and luteal phases was found in 33/49 (67%) and 23/40 
(58%) of women, respectively (p = 0.5).
Conclusions: On the mRNA and protein levels, OCT-4 is not differentially expressed during the menstrual cycle. 
Endometrial OCT-4 is not involved in or modulated by hormone-induced cyclical changes of the endometrium.
Background
Octamer-4 (OCT-4) is a homeodomain transcription fac-
tor of the Pit-Oct-Unc transcription factor family [1-3]. A
transcription factor is defined as a protein binding to spe-
cific DNA binding domains and subsequently regulating
the transcription from DNA to RNA by activation or
repression of RNA polymerase [4]. Specifically, OCT-4
regulates tissue- and cell-specific transcription via the
consensus motif ATGCAAAT and its expression is
restricted to pluripotent cells. Loss of OCT-4 expression
may be associated with the loss of pluripotentiality [5].
During embryogenesis, OCT-4 is initially active as a
maternal factor in the oocyte and remains active in
embryos throughout the preimplantation period. OCT-4
is involved in the self-renewal of undifferentiated embry-
onic stem cells and is therefore used as a marker of
embryonic stem cells [5-8].
OCT-4 has also been found to be expressed in malig-
nant tissues such as germ cell tumors, embryonic carci-
noma cells [9]. Furthermore, breast cancer cells express
OCT-4 [10] and OCT-4 is - among other embryonic gene
products - re-expressed in cancer cells [11]. Based on
these data and the fact that stem cells are undifferenti-
ated, immortal, and invasive, an etiologic role for stem
cells as clonogenic origin of various forms of cancer has
been proposed [11,12].
Cho et al. described the presence of stem cells in the
stroma of the basal layer of human endometrium based
on the presence of C-kit/CD 117, CD34, bcl-2, and Ki67
[13]. In a previous study, we demonstrated that OCT-4 is
also expressed in the human endometrium, lending fur-
ther support to the hypothesis of endometrial regenera-
tion by local stem cells in endometrial tissue [12]. This
concept is also supported by the presence of clonogenic
epithelial and stromal cells in human endometrium act-
ing as putative stem cells [14,15]. It has been speculated
that local tissue-specific stem cells are involved in the
regeneration and maintenance of the endometrial lining
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during the follicular phase and the menstruation. This
concept, however, has been challenged by evidence that
OCT-4 genetic ablation did not result in abnormalities in
homeostasis and regenerative capacity in rodent studies
[16].
To further investigate the role of OCT-4 in human
endometrial physiology, we performed a prospective
study to assess the mRNA and protein expression of
OCT-4 in follicular and luteal phase endometrium. We
hypothesized that OCT-4 is differentially regulated in the
follicular and luteal phases of the menstrual cycle. Specif-
ically, we aimed to answer the question whether or not
OCT-4 is overexpressed during endometrial proliferation
in the follicular phase and downregulated during the
secretory transformation of the endometrium in the
luteal phase.
Methods
Patients
We performed a prospective, single center cohort study
between September 2006 and March 2007 in a popula-
tion of 89 consecutive patients undergoing hysteroscopy
and endometrial sampling at the Endoscopy Unit of the
Department of Gynecologic Endocrinology and Repro-
ductive Medicine at Vienna Medical University, Vienna,
Austria. The mean age of the patients was 33.9 ± 5.2
years. All women had regular menstrual cycles during the
last 6 months (menstrual cycle length 25-35 days) and did
not take any hormone therapy. Menstrual phase assess-
ment was based on the date of the last menstrual period
with the luteal and follicular phases determined by half-
ing the median number of cycle days of the last three
menstrual cycles of the patient and confirmed by histo-
pathological analysis of the endometrial specimen. Indi-
cations for surgery were primary sterility (n = 32),
secondary sterility (n = 34), endometriosis and/or dys-
menorrhea (n = 10), recurrent pregnancy loss (n = 4),
chronic pelvic pain (n = 4), and others (n = 5). Written
informed consent was obtained by all patients.
Reverse transcriptase polymerase chain reaction (RT-PCR)
For RNA extraction frozen tissue samples were triturated
and total RNA was extracted using the TRI REAGENT
method (Molecular Research Centre, Inc., OH, USA).
RNA concentration was determined by measuring the
optical density at 260 nm. 1 μg RNA was reversely tran-
scribed into first strand complementary DNA (cDNA)
using Superscript (Invitrogen Ltd., Paisley, UK). The
resulting cDNA was amplified by polymerase chain reac-
tion (PCR) using primers specific for OCT-4 [11]. The
following primers were used for RT-PCR reactions: OCT
4 forward 5'-GAC AAC AAT GAA AAT CTT CAG GAG
A-3' and OCT reverse 5'-TTC TGG CGC CGG TTA
CAG AAC CA-3'. The PCR was started with a denaturing
step at 94°C for 5 min and the amplification of the 218 bp
product was performed for 35 cycles at 94°C for 30 sec,
61°C for 30 sec and 72°C for 30 sec, and a final extension
at 72°C for 10 min. As control for genomic DNA we used
extracted RNA only (no cDNA). As positive control for
the expression of OCT -4 we used RNA from embryonic
carcinoma of testis. Human glyceraldehyd-3-phosphate
dehydrogenase (GAPDH) was amplified in parallel reac-
tions as a housekeeping reference gene serving as an
internal control for the quantity and quality of the cDNA.
Primers for GAPDH were: forward 5'-TCT GGT AAA
GTG GAT ATT GTT G-3' and reverse 5'-GAT GGT GAT
GGG ATT TCC-3'. The amplified product for GAPDH
has a size of 156 base pairs. Amplified samples were sepa-
rated on 1.5% agarose gels in the presence of ethidium
bromide and visualized by the Eagle Eye System (Strata-
gene, Amsterdam, The Netherlands). Quantitative analy-
sis was performed by densitometric scanning of the gels
using the AlphaDigiDoc 1000 software (Alpha Innotech
Corp., San Leonardo, CA). OCT-4 mRNA levels were
determined by calculating the OCT-4/GADPH ratios
(Figure 1). We optimized all PCR steps with respect to
sensitivity, reproducibility, and linearity: different tem-
plate, enzyme, and primer concentrations, reaction times,
and temperatures were tested. The resulting optimal con-
ditions are given above. Since the technician and the
scoring person were both blinded to the menstrual phase
of the specific samples, the samples have been placed in
the order of sampling and not arranged according to
menstrual phase.
Although the mRNA quantities varied, expression of
OCT-4 was detected in all samples analyzed (Figure 2).
By including control reactions with input RNA instead of
cDNA obtained after reverse transcription of RNA, we
are confident that the OCT-4 PCR product of the endo-
metrial samples is not due to genomic DNA contamina-
tion.
Increased mRNA levels were evaluated relative to
GAPDH, ie mRNA levels equivalent or less than GAPDH
were considered normal, mRNA levels above the levels
measured for GAPDH were considered indicative of
increased transcription.
For confirmation of OCT-4 expression in endometrial
tissue, we performed Western Blot experiments, but were
not able to consistently demonstrate OCT-4 protein in
the frozen tissue samples used (see Additional File 1, Fig-
ure S1).
Immunohistochemistry
We used formalin-fixed, paraffin-embedded tissue sam-
ples of endometrium from 89 patients. From these sec-
tions we performed immunohistochemical staining using
a primary antibody recognizing OCT-4 (OCT-4 [C-10]:
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ously described [12]. Stained sections were scored
according to the immunoreactive score (IRS) described
by Remmele and Stegner [17]. The IRS results from the
multiplication of a staining intensity score (negative = 0;
weak = 1; moderate = 2; strong = 3) and the percentage
score of immunopositive cells (no staining = 0, 1-10% of
stained cells = 1; 11-50% of stained cells = 2, 51-80% of
stained cells = 3; 81-100% of stained cells = 4). Each sam-
ple was scored according to these IRS criteria. An IRS of
≥6 was considered to indicate ' increased expression ' of
OCT-4. Figures 3A, B, C, and 3D show examples with a
strong (A, B, C) and an absent (D) staining intensity,
respectively.
Statistics
Categorical variables were analyzed by x2-test. Multiple
comparisons were corrected using Bonferroni's correc-
tion. OCT-4 mRNA and protein expression were corre-
lated using Pearson's correlation coefficient. A univariate
regression model was used to assess the influence of day
of the menstrual cycle, using 3-day intervals, on OCT-4
protein expression, comparing an IRS <6 vs. ≥ 6. All p-
values were two-tailed and 95% CI were calculated. A p-
value < 0.05 was considered statistically significant. We
used the statistical software SPSS 11.0 for Windows
(SPSS Inc., Chicago, IL) for statistical analyses.
Results
We included 89 patient samples. The mean age of the
patients was 33.9 ± 5.2 years. Of these, 49 were in the fol-
licular phase and 40 were in the luteal phase. All patients
underwent hysteroscopy and endometrial sampling. Indi-
cations for surgery were primary sterility (n = 32), sec-
ondary sterility (n = 34), endometriosis and/or
dysmenorrhea (n = 10), recurrent pregnancy loss (n = 4),
chronic pelvic pain (n = 4), others (n = 5). OCT-4 mRNA
was detected in all samples (Figure 1). Increased OCT-4
mRNA levels were observed in 62/89 (70%) samples.
Comparing the number of samples with increased OCT-4
mRNA levels in the follicular and luteal phases, we found
no statistically significant difference (35/49 [71%] vs. 27/
40 [68%], respectively (p = 0.9). Figure 2 demonstrates
OCT-4 cDNA expression in endometrial samples of the
follicular and luteal phases.
Figure 1 OCT-4 cDNA expression after RT-PCR relative to GADPH in 89 patients. OCT-4 = Octamer-4; cDNA = complementary deoxyribonucleic 
acid; RT-PCR = reverse transcriptase polymerase chain reaction; GADPH = glyceraldehyde-3-phosphatedehydrogenase. Each bar represents one pa-
tient; values are given for each patient representing OCT-4 cDNA expression relative to the expression of GADPH with 1 denominating equivalent 
expression. The lowest (0.4) and highest (2.6) values are shown.
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OCT-4 protein overexpression was identified in 56/89
(63%) samples. OCT-4 protein overexpression in the folli-
cular and luteal phase was found in 33/49 (67%) and 23/
40 (58%) of women, respectively (p = 0.5). In a univariate
regression model, the day of the menstrual cycle, using 3-
day intervals, did not influence OCT-4 protein expres-
sion, when comparing an IRS <6 vs. ≥ 6 (p = n.s).
Increased mRNA levels and increased OCT-4 protein
expression were significantly correlated (Pearson's corre-
lation coefficient 0.8). Figure 3 shows follicular and luteal
phase endometrial samples with and without OCT-4
overexpression. We found that OCT-4 expression was
restricted to the plasma of epithelial endometrium cells.
This pattern of expression was present in the follicular
and luteal phases of the menstrual cycle with no discern-
ible differences.
Discussion
In the present study we assessed the mRNA levels and
protein expression of OCT-4 in human endometrium.
We found that human endometrium contains potentially
pluripotent OCT-4-expressing cells with increased OCT-
4 mRNA levels observed in 70% of samples. OCT-4, how-
ever, is not differentially expressed on the mRNA and
Figure 2 OCT-4 cDNA expression in endometrial samples using RT-PCR. OCT-4 = Octamer-4; cDNA = complementary deoxyribonucleic acid; RT-
PCR = reverse transcriptase polymerase chain reaction; GADPH = glyceraldehyde-3-phosphatedehydrogenase. (A) lanes 1,2,5,6,7,8,10,11,12, and 16: 
patient samples from the luteal phase; lanes 3,4,9,13,14,15,17, and 18: patient samples from the follicular phase. (B) lane 1 = positive control (embry-
onic carcinoma); lane 2 = negative control (water); lanes 3,4, and 7: patient samples from the luteal phase: lanes 5 and 6: patient samples from the 
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Figure 3 Immunohistochemical staining for OCT-4. OCT-4 = Octamer-4; (A) OCT-4 overexpression in a sample of follicular phase endometrium. 
The picture demonstrates selected tissue compartments, ie three endometrial glands and surrounding endometrial stroma The brown staining shows 
OCT-4 expression in the cytosol of glandular cells. Magnification ×100. (B) OCT-4 overexpression in a sample of luteal phase endometrium. The picture 
demonstrates selected tissue compartments, ie two secretory endometrial glands and surrounding endometrial stroma The brown staining shows 
OCT-4 expression in the cytosol of glandular cells. Magnification ×200. (C) OCT-4 overexpression in a sample of embryonic carcinoma of the testis 
serving as positive control. Magnification ×200. (D) Section of embryonic carcinoma of the testis stained with IgG1 as described in Materials and Meth-
ods serving as negative control. Magnification ×200.
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protein levels during the menstrual cycle. We conclude
that human endometrium may contain pluripotent cells.
The stem cell marker OCT-4 is widely expressed in
human endometrium, but it is not involved in or modu-
lated by hormone-dependent cyclical changes of the
endometrium.
Our results compare with other studies in that OCT-4
h a s  b e e n  d e m o n s t r a t e d  t o  b e  e x p r e s s e d  i n  t h e  h u m a n
endometrium [12]. From a functional perspective, Taylor
et al. demonstrated donor-derived endometrial cells in
bone-marrow transplantation recipients indicating a
functional interaction of potential uterine and nonuterine
stem cells [14]. It has to be acknowledged, however, that
there is not enough evidence available at this time,
including our own results, to convincingly conclude that
OCT-4 positive cells in the endometrium are pluripotent.
We found that OCT-4 expression was restricted to the
cytosol of epithelial endometrium cells. This pattern of
expression was present in the follicular and luteal phases
of the menstrual cycle with no discernible differences.
This rejects our study hypothesis that OCT-4 is overex-
pressed during endometrial proliferation in the follicular
phase and downregulated during the secretory transfor-
mation of the endometrium in the luteal phase. This find-
ing does not support the concept of cyclical endometrial
renewal based on hormonally modulated local OCT-4
expressing cells. Rather, it supports the notion of a con-
stant and sex steroid-independent pool of renewable
stem cells from which cells may be recruited.
Our study has limitations. For example, the semiquanti-
tative technique of immunohistochemistry and the small
sample size may miss subtle differences in OCT-4 expres-
sion. Thus, we can only rule out a profound influence of
menstrual cycle-dependent changes of the human endo-
metrium on OCT-4 expression. Also, OCT-4 is a surro-
ga t e mar ker of st em ce ll pot en tial ra ther t han a dir ect
proof of pluripotency. Thus, other yet unknown factors
influencing the expression of OCT-4 may be present in
human endometrium.
Regarding the implications of our results for future
research, we suggest that the investigation of peri- and
postmenopausal endometrium may be worthwile. Such
experiments may determine whether or not endometrial
expression of OCT-4 - as demonstrated in this study -
will decrease at the end of the reproductive period. Also,
differential regulation of OCT-4 expression in women
with endometriosis may be a worthwile target of investi-
gation.
In conclusion, we evaluated the mRNA-transcription
and protein expression of the stem cell marker OCT-4 in
human endometrium and found that OCT-4 is frequently
expressed in human endometrium, but is not involved in
menstrual cycle regulation.
Conclusions
On the mRNA and protein levels, OCT-4 is not differen-
tially expressed during the menstrual cycle. Endometrial
OCT-4 is not involved in or modulated by hormone-
induced cyclical changes of the endometrium.
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